DRG Market Assessment reports

Schizophrenia is a chronic psychiatric disorder that requires sustained pharmacologic management to reduce psychotic episodes and maintain long-term symptom stability. It is a highly drug-treated…

Negative symptoms of schizophrenia—often occurring along with positive symptoms—include diminished emotional expression (affective flattening), reduced goal-directed behavior (avolition),…

The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…

The schizophrenia therapy market remains very competitive; atypical and typical antipsychotics play a dominant role. While the continued generic erosion of atypical antipsychotics influences…

Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug…

Most psychiatrists define TRS as a lack of response to at least two treatment changes. Currently, clozapine is the only approved drug for this condition, but its use is limited due to safety…

The schizophrenia therapy market is crowded and dominated by atypical and typical antipsychotics. Although the continued generic erosion of atypical antipsychotics influences psychiatrists’…

Managing the frequency and severity of psychotic episodes is the primary goal in the treatment of schizophrenia. Atypical antipsychotics are the preferred drug class, driven by physicians’…

CIAS (e.g., impaired attention / vigilance, memory, and/or executive function) negatively impacts patients’ daily activities, occupational and social functioning, and adherence to antipsychotic…

In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…

Clarivate Epidemiology’s coverage of schizophrenia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of schizophrenia for…